# a.) Amendments to the Specification

Please amend the paragraph at page 1, lines 15-16 to read as follows.

In accordance with the present invention, it there is provided a compound represented by the general formula (I);

Please amend the paragraph starting at page 7, line 10 and ending at page 8, line 1 to read as follows.

(wherein "p's" in individual amino acid residues are the same or different, and represent 0 or 1; Z¹ represents Ala, Phe or Pro; Z² represents Arg, Lys or Gln; Z³, Z¹⁵ and Z²¹ are the same or different, representing Gly or Pro; Z⁴ represents Arg, Lys, Met or Pro; Z⁵ represents Gly, Cys, Ala or Gln; Z⁶ represents Ala, Arg or Glu; Z⁶ represents Ala, Ile or Gln; Z⁶ represents Ala, Gly or Arg; Z⁰ represents Leu, Val or Pro; Z¹⁰ represents Asp, Arg or Gln; Z¹¹ represents Gly, Ser, Ala or Pro; Z¹² represents Leu or Pro; Z¹³ represents Asp, His or Pro; Z¹⁴ represents Ser or Pro; Z¹⁶ represents Gln or Lys; Z¹⁷ represents Gly, Thr or Leu; Z¹⁶ represents Gly, Pro or Val; Z¹⁰ represents Gly or Lys; Z²⁰ represents Ala or Ser; Z²² represents Gly or Ser; Z²³ represents Gly, Glu or Thr; Z²⁴ represents Arg, Lys, Ser or Pro; Z²⁵ represents Ser or Thr; Z²⁷ represents His or Tyr; Z²⁶ represents Asp or Glu; Z²⁰ and Z³⁶ are the same or different, representing Lys or Thr; Z³² represents Gly or Asn; Z³⁴ represents Leu or Thr; Z³¬ represents Arg or Lys; Z³⁰ represents Ile, Leu or Val; and Z⁴⁰ represents Glu, Gln, Ser or Tyr) Tyr).

Please amend the paragraph at page 12, lines 11-19 to read as follows.

The pharmaceutically acceptable salt of the Compound (I) can be obtained in a conventional manner. More specifically, the acid addition salt or organic base addition salt of the Compound (I) can be obtained obtained by dissolving the Compound (I) in an aqueous solution of an acid or an organic base corresponding thereto and then

freeze-drying the solution. The metal salt of the Compound (I) can be obtained by dissolving the Compound (I) in an aqueous solution containing the corresponding metal ion and purifying the solution by gel filtration or by HPLC.

Please amend the paragraphs at page 31, lines 18-23 to read as follows.

## Example 1

Synthesis of Compound Ia-1

Please amend the paragraphs at page 34, lines 20-23 to read as follows.

# Example 2

Synthesis of Compound Ia-2

Please amend the paragraph at page 35, lines 1-6 to read as follows.

Fmoc-Val-OH, Fmoc-Asn (Trt)-OH, Fmoc-Thr (t- (t-Bu)

Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp (Ot-Bu)-OH, Fm Fmoc

oc-Tyr (t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg (Pmc)

-OH, Fmoc-Arg (Pmc)-OH, Fmoc-Lys (Boc)-OH, Fm Fmoc

oc-Gln (Trt)-OH, Fmoc-Val-OH, Fmoc-Lys (Boc)

-OH, Fmoc-Leu-OH, and Fmoc-Val-OH.

Please amend the paragraphs at starting at page 35, lines 23 and ending at page 36, line 3 to read as follows.

## Example 3

Synthesis of Compound Ib-1

(CH<sub>3</sub>-CO-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-Lys-As Asn n-Ile-Arg-Arg-Val-Tyr-Asp-Ala-Leu-As Asn n-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-Ser-NH NH<sub>2</sub>, SEQ ID No.3)

Please amend the paragraph at page 36, lines 7-17 to read as follows.

Fmoc-Ser (t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH,

H, Fmoc-Asn (Trt)-OH, Fmoc-Met-OH, Fmoc-AlaOH, Fmoc-Met-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc

moc-Asn (Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH,

Fmoc-Asp (Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH, Fmoc

e-Val-OH, Fmoc-Arg (Pmc)-OH, Fmoc-Arg (Pmc)OH, Fmoc-Arg (Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn
(Trt)-OH, Fmoc-Lys (Boc)-OH, Fmoc-Gln (Trt)OH, Fmoc-Asp (Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH,

Fmoc-Ala-OH, Fmoc-Ser (t-Bu)-OH, Fmoc-Glu (Ot-Bu)

t-Bu)-OH, and Fmoc-Asn (Trt)-OH.

Please amend the paragraphs at page 37, lines 8-20 to read as follows.

## Example 4

Synthesis of Compound Ib-2

In the same manner as in Example 1, a carrier resin (30 mg) bonded with 14.7 .mu.mol of Fmoc-NH as a starting material was condensed sequentially with Fmoc-Met-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc
-Leu-OH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc
-Leu-OH, Fmoc-Ala-OH, Fmoc-Asp(Ot-Bu)-OH,
Fmoc-Tyr (t-Bu)-OH, Fmoc-Val-OH, Fmoc-Arg(P-Fmoc-Arg(P-mc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)-OH,
and Fmoc-Ile-OH.

Please amend the paragraphs at page 38, lines 12-17 to read as follows.

#### Example 5

Synthesis of Compound Ic-1

Please amend the paragraph starting at page 38, line 21 and ending at page 39, line 9 to read as follows.

Fmoc-Leu-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Leu-OH, Fmoc-Phe-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys

(Boc)-OH, Fmoc-Thr(t-Bu)-OH, Fmoc-Thr (t-Bu)

-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Leu

t-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Thr(t-Bu)-OH,

Fmoc-Glu(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmoc

c-Arg(Pmc)-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Arg

(Pmc)-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-Gly-OH,

Fmoc-Pro-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Lys(B (Boc)

c-)-OH, Fmoc-Val-OH, Fmoc-Gly-OH, Fmoc-Lys(B (Boc)

rt)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, Fmoc-His(T (Trt)

rt)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Gly-OH, Fmoc

-Arg(Pmc)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pmc)-OH,

H, and Fmoc-Ala-OH.

Please amend the paragraphs at page 40, lines 2-7 to read as follows.

#### Example 6

Synthesis of Compound Ia-3

[CH<sub>3</sub> -(CH<sub>2</sub>)<sub>10</sub> -CO-Leu-Asn-Trp-Ala-Ala-Glu-Val-£ <u>L</u>-eu <u>Ile</u>-Lys-Val-Gln-Lys-Arg-Arg-Ile-Tyr-Asp-£ <u>Ile</u> le-Thr-Asn-Val-Leu-Glu-Gly-Ile-Gln-Leu-£ <u>Ile</u> le-Ala-NH<sub>2</sub>, SEQ ID No.20]. Please amend the paragraph starting at page 41, line 25 and ending at page 42, line 8 to read as follows.

Fmoc-Leu-OH, Fmoc-Gln(Trt)-OH, Fmoc-Ile-OH,
Fmoc-Gly-OH, Fmoc-Glu(Ot-Bu)-OH, Fmoc-LeuOH, Fmoc-Val-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr
(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Asp(Ot-Bu)-OH,
Fmoc-Tyr(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Arg(P-(Pmc))
mc)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Lys(Boc)-OH,
Fmoc-Gln(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)
c)-OH, Fmoc-Leu-OH, Fmoc-Val-OH, Fmoc-Glu(Ot-Bu)
t-Bu)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Tr Trp
p(Boc)-OH, Fmoc-Asn (Trt)-OH, and Fmoc-Leu-OH.

Please amend the paragraphs starting at page 43, line 6, and ending at page 44, line 1 to read as follows.

#### Example 7

Synthesis of Compound Ib-3

[CH<sub>3</sub>-(CH<sub>2</sub>)<sub>10</sub>-CO-Asn-Glu-Ser-Ala-Tyr-Asp-Gln-£ <u>L-</u>ys-Asn-Ile-Arg-Arg-Arg-Val-Tyr-Asp-Ala-£ <u>Leu</u>eu-Asn-Val-Leu-Met-Ala-Met-Asn-Ile-Ile-<del>S</del> <u>Ser</u>er-NH<sub>2</sub>, SEQ ID No.21].

In the same manner as in Example 6, a carrier resin (100 mg) bonded with 20 .mu.mol of Fmoc-NH as a starting material was condensed sequentially with Fmoc-Ser(t-Bu)-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Ile-OH, Fmoc-Ala-OH, Fmoc-Met-OH, Fmoc-Met-OH, Fmoc-Met-OH, Fmoc-Met-OH, Fmoc-Wal-OH, Fmoc-

moc-Asn(Trt)-OH, Fmoc-Leu-OH, Fmoc-Ala-OH,

Fmoc-Asp(Ot-Bu)-OH, Fmoc-Tyr(t-Bu)-OH, Fmo Fmoc

c-Val-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Arg(Pmc)- Fmoc-Arg(Pmc)-OH,

OH, Fmoc-Arg(Pmc)-OH, Fmoc-Ile-OH, Fmoc-Asn

(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)- Fmoc-Gln(Trt)-OH,

OH, Fmoc-Asp (Ot-Bu)-OH, Fmoc-Tyr (t-Bu)-OH,

Fmoc-Ala-OH, Fmoc-Ser(t-Bu)-OH, Fmoc-Glu(Ot-Bu)

t-Bu)-OH, and Fmoc-Asn (Trt)-OH.